We delivered another strong quarter with results that reflect the breadth of demand across the portfolio. All-in revenue grew 7% or 5% organically, with all five segments posting positive organic growth. Adjusted EBITDA margin expanded 80 basis points to 25.9% as operational execution on incremental volume more than offset input cost inflation and facility consolidation costs during the quarter. Incremental margins were 38%, from 25% in Q1, the healthy product mix driven by our growth platforms.

Adjusted EPS was $2.74 per share, up 12% year-over-year, marking another quarter of double-digit earnings growth. Orders increased 16% year-over-year and outpaced shipments with book-to-bill at 1.06, extending strong order momentum of recent quarters and improving our visibility into the second half of the year. Our balance sheet remains a competitive advantage, and we continue to invest capital behind our businesses. During the quarter, we advanced capacity expansion projects to support growth as well as productivity investments to drive margin improvement across the portfolio.

Industrial M&A markets have improved this year, and our acquisition pipeline has a number of interesting opportunities in attractive end markets. Given our first half performance, the momentum in our end markets, and the visibility we have in the second half, we are raising our full year adjusted EPS guidance. We are committed to delivering double-digit adjusted EPS growth consistent with Dover's long-term performance trajectory. Growth was driven by strong demand in aerospace and defense components, fluid dispensing, and industrial winches, along with continued stabilization in the North American vehicle aftermarket.

What went well
  • Dover delivered a strong quarter with all-in revenue up 7% (5% organic) and all five segments posting positive organic growth, led by its secular-growth-exposed markets, which now represent approximately 25% of the portfolio, up from 20% at the end of Q1.
  • Adjusted EBITDA margin expanded 80 basis points to 25.9% and incremental margins jumped to 38% from 25% in Q1, driven by favorable product mix from the growth platforms, as operational execution more than offset input-cost inflation and facility-consolidation costs.
  • Adjusted EPS rose 12% to $2.74 (GAAP diluted EPS from continuing operations of $2.31, up 14%), marking another quarter of double-digit earnings growth, prompting a raise to full-year adjusted EPS guidance.
  • Bookings were again the highlight: orders grew 16% year over year with a 1.06 book-to-bill (trailing-twelve-month bookings up 15%), broad-based across all five segments and improving visibility into the second half.
  • Heat exchangers delivered their best quarter ever on liquid-cooling demand for data centers, with Dover actively working to double SWEP capacity over the next 12 months, and clean energy cryogenic/LNG and CO2 refrigeration order books expanded meaningfully.
  • Year-to-date free cash flow rose 23% to $320 million (8% of revenue), and management noted an improved industrial M&A pipeline with balance-sheet flexibility to play offense on capital deployment.
What went wrong
  • A refrigeration facility consolidation fell short on production throughput while ramping labor, which CEO Rich Tobin owned personally and estimated cost roughly a point to a point-and-a-half of organic growth in the quarter, with associated redundant-facility margin pressure.
  • The Pumps & Process Solutions segment grew only slightly as Polymer Processing faced a tough comparison that muted the segment's top line (though it exited Q2 with a book-to-bill above one).
  • Heat exchanger growth was capacity-constrained: management confirmed second-quarter growth would have been higher had additional SWEP capacity been available, as demand outstrips supply.
  • Absolute bookings dollars declined sequentially from Q1 (even as book-to-bill stayed above one at 1.06), and management declined to talk up revenue conversion despite strong order growth.

Guidance Changes

MetricPeriodCurrent guidance
Adjusted EPSFY2026Raised; committed to double-digit adjusted EPS growth consistent with Dover's long-term trajectory
Organic revenue growthFY2026Raised; positive organic growth expected across all five segments, led by secular-growth markets
Free cash flowFY2026Unchanged at 14%-16% of revenue (H2 seasonally stronger on working-capital liquidation)
Capital expendituresFY2026Unchanged at $190M-$210M
Space-related revenueFY2026~$50 million, with order rates signaling significant momentum

Performance Breakdown

MetricYoYNote
Total revenue +7% (+5% organic) to $2.19B All five segments grew organically, led by secular-growth markets and broad-based constructive trading conditions.
Adjusted EPS +12% to $2.74 Volume leverage, favorable mix and cost discipline; GAAP diluted EPS from continuing operations up 14% to $2.31.
Clean Energy & Fueling organic +9% LNG/space cryogenic components and healthy retail fueling (dispensers, software, below-ground); margin +170 bps on volume leverage and acquisition integration.
Climate & Sustainability organic +8% Best-ever heat-exchanger quarter on data center liquid cooling and European heat-pump recovery, partly offset by a refrigeration throughput shortfall.
Engineered Products organic +2% Aerospace/defense, fluid dispensing and industrial winches plus vehicle-aftermarket stabilization; margin +100 bps, with muted top line partly self-inflicted by avoiding dilutive Vehicle Service Group sales.
Pumps & Process Solutions organic Slightly positive Strength in AI/energy infrastructure, single-use biopharma and industrial pumps offset by a tough Polymer Processing comp; segment margin +170 bps to a record ~35%.
Adjusted EBITDA margin +80 bps to 25.9% Incremental margins of 38% from healthy growth-platform mix more than offset inflation and facility-consolidation costs.

Earnings Call Themes & Trends

TopicPrevious mentionCurrent periodTrend
Data center liquid coolingEmerging opportunityHeat exchangers (SWEP brazed plate) had their best quarter ever with demand outstripping supply; capacity being doubled over 12 months (coming on sequentially into 2027), plus new cryogenic cooling and OPW connector/trench exposure to hyperscalers.
Secular growth portfolio shift~20% of revenue (end of Q1)~25% of 2026 revenue across aerospace/defense, power-gen (steam/gas turbines), single-use biopharma, CO2 refrigeration, liquid cooling and space (~$50M), where most acquisition capital has been deployed.
Refrigeration facility consolidationPlanned plant consolidationThroughput fell short during the labor ramp, costing ~1-1.5 pts of organic growth; the old plant is ~three-quarters closed, and management expects materially better H2 profitability as throughput and fixed-cost absorption improve.
CO2 refrigeration adoptionRegulation-drivenAdoption now driven by total-cost-of-ownership economics rather than regulation; the removal of a time-based EPA mandate is viewed as favorable, extending demand over a multi-year period with an accelerating backlog.
Capital allocation and M&ALeaning toward capital return amid scarce, expensive assetsMore assets are coming to market at potentially reasonable valuations; Dover is keeping powder dry for M&A but would pivot to capital return (stock viewed as cheap) if deals do not materialize.
Order-to-revenue conversion and cycle durabilityStrong multi-quarter order momentumManagement resisted talking up revenue beyond guidance given short-cycle volatility, but sees visibility into 2027 across its cycles and no end markets expected to turn negative next year.

Q&A Summary

Jeff Sprague (Vertical Research) asked whether the refrigeration throughput issue is on a consolidated basis and whether it disrupted customers, and how weak Polymer Processing was.
Tobin confirmed the ~1-1.5 pt impact is consolidated, said Dover has been late on some deliveries but is not aware of losing share, and characterized Polymer Processing as lumpy - a drag on the top line but slightly accretive to profit versus expectations, with book-to-bill above one exiting Q2.
Scott Davis (Melius) asked whether the removal of the EPA CO2 mandate is pushing customer demand out and about the new data center cryogenic cooling opportunity.
Tobin said the CO2 shortfall was Dover's own delivery inability, not a demand push-out, and that no time-based mandate is actually better as adoption accelerates over multiple years; the cryogenic valve/connector/piping products bought for LNG are now becoming viable for data center cooling.
Amit Mehrotra (UBS) pressed on absolute bookings declining sequentially despite the 1.06 book-to-bill and asked to quantify the SWEP capacity add.
Tobin said as revenue rises the book-to-bill bogey grows, and being above one across the entire portfolio is rare and broad-based; he declined to quantify SWEP capacity for competitive reasons but confirmed it comes on sequentially into 2027 and that growth would have been higher with more capacity.
Nigel Coe (Wolfe) asked whether the lost refrigeration revenue returns in H2 and whether mid-30%+ incremental margins are achievable in the back half.
Tobin said throughput will rise sequentially, flowing into fixed-cost absorption and margins, so H2 profitability should be materially better than H1; the 38% incrementals reflect the rest of the portfolio executing well while refrigeration is fixed.
Deane Dray (RBC) asked how Dover landed on 2x heat-exchanger capacity and the margin impact of the ramp.
Tobin said the business is hard to ramp (a competitive moat), and that after two-plus years of adding fixed cost ahead of revenue that diluted margins, demand has now inflected enough that revenue is outpacing capital deployment, so margins are expanding even as capacity grows.
Andy Kaplowitz (Citi) asked what 'improved M&A markets' means and how M&A weighs against buybacks.
Tobin said more assets are coming to market than in the prior two to three years, so Dover wants to keep powder dry to see if it can buy at the right price; if it does not deploy into M&A, it would cycle back to capital return since the stock looks cheap.
Andrew Obin (Bank of America) asked how Dover's biopharma differs from peers and why revenue is not showing more torque from strong bookings.
Tobin said Dover's biopharma is largely consumables (connectors, pumps, flow meters) on running systems plus successful new products, and that he will not talk up revenue ahead of guidance but would revisit the outlook after Q3 if orders keep surging.
Joe Ritchie (Goldman Sachs) and Chris Snyder (Morgan Stanley) asked about order-to-revenue conversion and the SWEP capacity ramp risk relative to refrigeration.
Tobin cautioned against extrapolating backlog math given short-cycle timing volatility, said Dover will maximize conversion, and noted less concern about SWEP because it is the most highly automated business in the portfolio whereas the refrigeration issues were driven by labor ramp; capacity comes on sequentially into 2027.

More on DOVER Corp

Reported 2026-07-23 · figures from the DOVER Corp Q2 2026 earnings call.

See how VectorShift works for your firm

Request Demo